相似文献
1
Editorial: Perspectives in pharmacological therapy targeting cellular metabolic pathways in respiratory diseases.
Front Pharmacol. 2023 Nov 27;14:1324586. doi: 10.3389/fphar.2023.1324586. eCollection 2023.
2
Autophagy Augmentation to Alleviate Immune Response Dysfunction, and Resolve Respiratory and COVID-19 Exacerbations.
Cells. 2020 Aug 24;9(9):1952. doi: 10.3390/cells9091952.
3
Drugs against metabolic diseases as potential senotherapeutics for aging-related respiratory diseases.
Front Endocrinol (Lausanne). 2023 Apr 3;14:1079626. doi: 10.3389/fendo.2023.1079626. eCollection 2023.
4
Mitochondrial Dysfunction as a Pathogenic Mediator of Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis.
Ann Am Thorac Soc. 2018 Dec;15(Suppl 4):S266-S272. doi: 10.1513/AnnalsATS.201808-585MG.
5
Targeting the renin angiotensin system for respiratory diseases.
Adv Pharmacol. 2023;98:111-144. doi: 10.1016/bs.apha.2023.02.002. Epub 2023 Mar 21.
6
Metabolic reprogramming in the pathogenesis of chronic lung diseases, including BPD, COPD, and pulmonary fibrosis.
Am J Physiol Lung Cell Mol Physiol. 2018 Apr 1;314(4):L544-L554. doi: 10.1152/ajplung.00521.2017. Epub 2018 Jan 4.
7
[Advances in research on the relationship between changes in cellular metabolism and lung diseases].
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021 Sep;33(9):1145-1148. doi: 10.3760/cma.j.cn121430-20210119-00081.
8
Long-term management of patients with end-stage lung diseases.
Best Pract Res Clin Anaesthesiol. 2017 Jun;31(2):167-178. doi: 10.1016/j.bpa.2017.07.007. Epub 2017 Jul 25.
9
Metabolic reprogramming: A driver of cigarette smoke-induced inflammatory lung diseases.
Free Radic Biol Med. 2021 Feb 1;163:392-401. doi: 10.1016/j.freeradbiomed.2020.12.438. Epub 2020 Dec 30.
10
The protective effects of baicalin for respiratory diseases: an update and future perspectives.
Front Pharmacol. 2023 Mar 16;14:1129817. doi: 10.3389/fphar.2023.1129817. eCollection 2023.
本文引用的文献
1
Cancer statistics, 2022.
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
2
Mitochondrial DNA mutations contribute to high altitude pulmonary edema via increased oxidative stress and metabolic reprogramming during hypobaric hypoxia.
Biochim Biophys Acta Bioenerg. 2021 Aug 1;1862(8):148431. doi: 10.1016/j.bbabio.2021.148431. Epub 2021 Apr 14.
3
Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer: Real-World Incidence, Risk Factors, and Management Practices Across Six Health Care Centers in North Carolina.
Chest. 2021 Aug;160(2):731-742. doi: 10.1016/j.chest.2021.02.032. Epub 2021 Feb 20.
4
Chronic pulmonary aspergillosis: prevalence, favouring pulmonary diseases and prognosis.
Eur Respir J. 2021 Aug 19;58(2). doi: 10.1183/13993003.03345-2020. Print 2021 Aug.
5
Complex interplay between autophagy and oxidative stress in the development of pulmonary disease.
Redox Biol. 2020 Sep;36:101679. doi: 10.1016/j.redox.2020.101679. Epub 2020 Aug 11.
6
Non-surgical treatment options for pulmonary aspergilloma.
Respir Med. 2020 Apr;164:105903. doi: 10.1016/j.rmed.2020.105903. Epub 2020 Feb 19.
7
The Hsp27-Mediated IkBα-NFκB Signaling Axis Promotes Radiation-Induced Lung Fibrosis.
Clin Cancer Res. 2019 Sep 1;25(17):5364-5375. doi: 10.1158/1078-0432.CCR-18-3900. Epub 2019 May 24.
8
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68. doi: 10.1164/rccm.201807-1255ST.
9
Dominant-negative SMARCA4 mutants alter the accessibility landscape of tissue-unrestricted enhancers.
Nat Struct Mol Biol. 2018 Jan;25(1):61-72. doi: 10.1038/s41594-017-0007-3. Epub 2017 Dec 11.
10
Multistate point-prevalence survey of health care-associated infections.
N Engl J Med. 2014 Mar 27;370(13):1198-208. doi: 10.1056/NEJMoa1306801.
Zotero 插件